The independent source for health policy research, polling, and news.
681-700 of 704 results
A study published in Health Affairs examines how physician-patient interactions often present missed opportunities to control patients’ health care spending.
An MIT economist and Harvard oncologist propose offering loans to patients to cover the cost of expensive, curative drugs, financed by private sector investment in loan securities.
Valeant Pharmaceuticals, the company that makes Seconal, the drug most commonly used in prescribed for terminally ill patients who want to end their lives, physician-assisted suicide, has doubled the price to more than $3,000.
More Medicare Part D drug plans are requiring coinsurance rather than copayments for more types of medications, making beneficiaries’ costs less predictable.
The proposal that Medicare made this month to better control prescription drug costs involves testing strategies used with some success in the private sector.
New Hampshire is expanding its website that lists the cost of specific medical procedures to include dental treatments and 65 prescription drugs. California is expanding its report cards on large medical groups to include cost of medical services by an average patient.
Regulators unveiled a two-part plan that will change payments and test ways in which the Medicare Part B program can change the incentives that some policy experts say encourage doctors to choose higher-cost medications.
There is more than one reason prices are rising, and no single solution.
The Centers for Medicare & Medicaid Services says access to special, lower-cost pharmacies has improved for Medicare beneficiaries in urban areas.
New hepatitis C drugs boast cure rates of at least 95 percent. But states are restricting their use for Medicaid patients and prisoners because the cost is so high.
In an analysis published Monday in JAMA Internal Medicine, researchers found that text message reminders help patients do better when it comes to taking their medicines. But questions about the specific ways to make the most of this strategy remain.
Heated battle expected over November ballot proposal to curb state’s prescription drug costs, as pharmaceutical industry opens its pocketbook to defeat the measure.
Experimental drugs might help desperate patients, but don’t count on an easy cure.
Some medicines, particularly intravenous treatments, are not listed in plans’ pharmacy benefit section and, therefore, it’s difficult to confirm coverage specifics.
Treating Hep C is expensive, but new drugs can quickly cure the disease, ultimately saving money.
The advocacy arm of the American Cancer Society said Wednesday that federal and state governments should move to restrict insurers from charging patients a percentage of the cost of their prescription drugs.
Only 16 percent of the popular plans cover all 10 of the most common drug regimens and charge less than $100 a month in consumer cost sharing, according to a report by Avalere Health.
Because of the complexity of insurance available through healthcare.gov and state exchanges, and the broad variation in how prescription drugs are covered, experts encourage consumers to compare options to figure out which one best fits their needs.
For beneficiaries, staying in their current plans could prove costly so advocates urge them to check out the alternatives.
Lawmakers, insurers and others have floated proposals to combat the spike in prescription drug prices, but will any of them gain traction?
© 2026 KFF